Effects of xylazine and/or butorphanol or neostigmine on myoelectric activity of the cecum and right ventral colon in female ponies.
Effects of xylazine HCl (0.5 mg/kg of body weight, IV) and/or butorphanol tartrate (0.04 mg/kg, IV) or neostigmine methylsulfate (0.022 mg/kg, IV) on myoelectric activity of the cecum and right ventral colon were studied in 4 conscious female ponies. Eight bipolar Ag/AgCl electrodes were sequentially placed on the seromuscular layer of the cecum (6 electrodes) and right ventral colon (2 electrodes). Recordings began 30 minutes before and continued for 90 minutes after drug administration. Each drug or drug combination was studied on 2 occasions in each pony. Two major patterns of coordinated spike bursts were identified. A series of coordinated spike bursts began at the cecal base and was conducted to the cecal apex (pattern I). A series of coordinated spike bursts began at the cecal apex, traversed the cecum, cecocolic orifice, and right ventral colon and was termed a progressive pattern (pattern II). Xylazine administration caused a significant decrease in patterns I and II for 20 minutes (P less than 0.05). Butorphanol tartrate administration caused a significant decrease in the progressive pattern for 10 minutes (P less than 0.05) without affecting the orally directed pattern. Administration of the combination of xylazine/butorphanol significantly decreased the frequency of pattern I for 40 minutes (P less than 0.05) and pattern II for 30 minutes (P less than 0.05). Neostigmine administration caused a significant increase in the frequency of pattern II for 30 minutes (P less than 0.05) without affecting pattern I (P greater than 0.05). Changes in conduction velocity of pattern I or II or the duration of spiking activity were not significantly different because of any treatment.
Department of Clinical Studies, New Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square 19348.
J A
JA
Rutkowski
M W
MW
Ross
K
K
Cullen
D000818:Animals; D002077:Butorphanol / Q000008:administration & dosage / Q000494:pharmacology*; D002432:Cecum / Q000187:drug effects / Q000502:physiology; D003106:Colon / Q000187:drug effects / Q000502:physiology; D004338:Drug Combinations; D004576:Electromyography / Q000662:veterinary; D005260:Female; D006736:Horses / Q000502:physiology*; D007420:Intestine, Large / Q000187:drug effects* / Q000502:physiology; D009019:Morphinans / Q000494:pharmacology*; D009388:Neostigmine / Q000494:pharmacology*; D013843:Thiazines / Q000494:pharmacology*; D014991:Xylazine / Q000494:pharmacology*
D004338:Drug Combinations; D009019:Morphinans; D013843:Thiazines; D014991:Xylazine; D009388:Neostigmine; D002077:Butorphanol